|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADAMTS12 |
Gene summary for ADAMTS12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADAMTS12 | Gene ID | 81792 |
| Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 12 | |
| Gene Alias | PRO4389 | |
| Cytomap | 5p13.3-p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | D6REX0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81792 | ADAMTS12 | ATC11 | Human | Thyroid | ATC | 2.49e-06 | 5.02e-01 | 0.3386 |
| 81792 | ADAMTS12 | ATC12 | Human | Thyroid | ATC | 3.84e-45 | 1.03e+00 | 0.34 |
| 81792 | ADAMTS12 | ATC13 | Human | Thyroid | ATC | 5.47e-22 | 3.48e-01 | 0.34 |
| 81792 | ADAMTS12 | ATC2 | Human | Thyroid | ATC | 3.71e-05 | 4.34e-01 | 0.34 |
| 81792 | ADAMTS12 | ATC3 | Human | Thyroid | ATC | 5.52e-09 | 4.91e-01 | 0.338 |
| 81792 | ADAMTS12 | ATC4 | Human | Thyroid | ATC | 1.19e-64 | 1.35e+00 | 0.34 |
| 81792 | ADAMTS12 | ATC5 | Human | Thyroid | ATC | 6.51e-18 | 3.77e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003158928 | Thyroid | ATC | cell-substrate adhesion | 195/6293 | 363/18723 | 1.58e-15 | 1.17e-13 | 195 |
| GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
| GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
| GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
| GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
| GO:006056222 | Thyroid | ATC | epithelial tube morphogenesis | 156/6293 | 325/18723 | 4.48e-08 | 8.14e-07 | 156 |
| GO:009028721 | Thyroid | ATC | regulation of cellular response to growth factor stimulus | 140/6293 | 304/18723 | 3.91e-06 | 4.33e-05 | 140 |
| GO:004801212 | Thyroid | ATC | hepatocyte growth factor receptor signaling pathway | 12/6293 | 13/18723 | 1.85e-05 | 1.69e-04 | 12 |
| GO:003461228 | Thyroid | ATC | response to tumor necrosis factor | 116/6293 | 253/18723 | 3.22e-05 | 2.68e-04 | 116 |
| GO:00020624 | Thyroid | ATC | chondrocyte differentiation | 54/6293 | 106/18723 | 1.67e-04 | 1.14e-03 | 54 |
| GO:00614484 | Thyroid | ATC | connective tissue development | 112/6293 | 252/18723 | 2.08e-04 | 1.38e-03 | 112 |
| GO:000315825 | Thyroid | ATC | endothelium development | 66/6293 | 136/18723 | 2.16e-04 | 1.42e-03 | 66 |
| GO:007135627 | Thyroid | ATC | cellular response to tumor necrosis factor | 102/6293 | 229/18723 | 3.52e-04 | 2.18e-03 | 102 |
| GO:00031598 | Thyroid | ATC | morphogenesis of an endothelium | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
| GO:00611548 | Thyroid | ATC | endothelial tube morphogenesis | 13/6293 | 20/18723 | 4.03e-03 | 1.73e-02 | 13 |
| GO:00717726 | Thyroid | ATC | response to BMP | 72/6293 | 165/18723 | 4.50e-03 | 1.86e-02 | 72 |
| GO:00717736 | Thyroid | ATC | cellular response to BMP stimulus | 72/6293 | 165/18723 | 4.50e-03 | 1.86e-02 | 72 |
| GO:00512163 | Thyroid | ATC | cartilage development | 81/6293 | 190/18723 | 5.70e-03 | 2.30e-02 | 81 |
| GO:007055513 | Thyroid | ATC | response to interleukin-1 | 63/6293 | 143/18723 | 5.82e-03 | 2.35e-02 | 63 |
| GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADAMTS12 | SNV | Missense_Mutation | c.4155N>C | p.Lys1385Asn | p.K1385N | P58397 | protein_coding | deleterious(0.01) | benign(0.176) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ADAMTS12 | SNV | Missense_Mutation | c.3760N>A | p.Asp1254Asn | p.D1254N | P58397 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ADAMTS12 | SNV | Missense_Mutation | c.1138N>A | p.Glu380Lys | p.E380K | P58397 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ADAMTS12 | SNV | Missense_Mutation | c.948N>C | p.Lys316Asn | p.K316N | P58397 | protein_coding | tolerated(0.83) | benign(0.086) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ADAMTS12 | SNV | Missense_Mutation | novel | c.4668N>T | p.Lys1556Asn | p.K1556N | P58397 | protein_coding | deleterious(0) | benign(0.282) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS12 | SNV | Missense_Mutation | rs371132100 | c.1810N>T | p.Arg604Trp | p.R604W | P58397 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ADAMTS12 | SNV | Missense_Mutation | novel | c.3244N>C | p.Ile1082Leu | p.I1082L | P58397 | protein_coding | tolerated(0.98) | benign(0) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| ADAMTS12 | SNV | Missense_Mutation | c.1576T>A | p.Cys526Ser | p.C526S | P58397 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| ADAMTS12 | SNV | Missense_Mutation | novel | c.3634N>T | p.Pro1212Ser | p.P1212S | P58397 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ADAMTS12 | SNV | Missense_Mutation | c.2441N>C | p.Lys814Thr | p.K814T | P58397 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-E9-A22B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |